Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

Prenetics Global Ltd (NASDAQ: PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.21
+3.12 (1.41%)
AAPL  262.82
+3.24 (1.25%)
AMD  252.92
+17.93 (7.63%)
BAC  52.57
+0.81 (1.56%)
GOOG  260.51
+6.78 (2.67%)
META  738.36
+4.36 (0.59%)
MSFT  523.61
+3.05 (0.59%)
NVDA  186.26
+4.10 (2.25%)
ORCL  283.33
+3.26 (1.16%)
TSLA  433.72
-15.26 (-3.40%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.